HLB Pharmaceutical Receives Approval for Generic Prostate Cancer Drug... Launch Planned for June
Elbitandi, a Generic Version of Xtandi, Receives Product Approval
HLB Pharmaceutical Accelerates Expansion of Oncology Business Focused on General Hospitals
HLB Pharmaceutical is expanding its oncology business by obtaining approval for a generic drug for prostate cancer treatment.
HLB Pharmaceutical Prostate Cancer Treatment Generic Drug ‘Elbitandi Soft Capsule 40mg’ Product Image. HLB Pharmaceutical
View original imageOn May 14, HLB Pharmaceutical announced that it had received product approval from the Ministry of Food and Drug Safety for Elbitandi Soft Capsule 40mg (active ingredient: enzalutamide), a treatment for metastatic castration-resistant prostate cancer. The company is aiming to launch the product at the end of June.
Elbitandi is a generic version of Xtandi, a prostate cancer treatment by Astellas Pharma Korea. Enzalutamide works by inhibiting androgen receptor signaling and is used for conditions such as metastatic castration-resistant prostate cancer. According to the pharmaceutical market research firm IQVIA, Xtandi recorded domestic sales of 43.2 billion won in 2023 and 43.8 billion won in 2024.
HLB Pharmaceutical plans to expand its oncology business, focusing on general hospitals, following this approval. The company intends to strengthen its portfolio of high value-added specialty drugs, starting with oncology generics and moving on to improved drugs and first generics.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Shin Dongseok, Executive Director of the Oncology Business Division at HLB Pharmaceutical, said, "We will leverage our general hospital network to facilitate the market entry of Elbitandi and continue to build our business capabilities in the general hospital sector. Since trust in products and prescribing experience are crucial in the oncology field, we will closely monitor the needs of medical professionals and market conditions to establish a stable business foundation."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.